Edition:
India

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

5,880JPY
9:28am IST
Change (% chg)

¥170 (+2.98%)
Prev Close
¥5,710
Open
¥5,790
Day's High
¥5,910
Day's Low
¥5,730
Volume
79,000
Avg. Vol
153,742
52-wk High
¥6,090
52-wk Low
¥2,133

Chart for

About

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Pharmaceutical business engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment... (more)

Overall

Beta: 1.18
Market Cap(Mil.): ¥119,311.40
Shares Outstanding(Mil.): 32.42
Dividend: 11.00
Yield (%): 0.60

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals

* Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd

19 Dec 2017

BRIEF-JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

* Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

26 Oct 2017

BRIEF-NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

* Says it and NanoCarrier Co., Ltd conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

10 Oct 2017

BRIEF-JCR Pharmaceuticals submits application for marketing approval of JR-051 for Fabry disease

* Says it has submitted an application for marketing approval on JR-051 (recombinant alpha-galactosidase A), an enzyme replacement therapy (ERT) for Fabry disease to Ministry of Health, Labour and Welfare

29 Sep 2017

BRIEF-JCR Pharmaceuticals completes share repurchase through ToSTNeT-3

* Says it completed repurchase of 854,100 shares of its common stock, for 2.62 billion yen in total, through ToSTNeT-3, on Sept. 22

22 Sep 2017

BRIEF- JCR Pharmaceuticals to repurchase shares

* Says it will repurchase up to 940,000 shares of its common stock, representing 2.7 percent of outstanding, on Sept. 22

21 Sep 2017

BRIEF- JCR Pharmaceuticals announces shareholding structure change

* Says its top shareholder GLAXO GROUP LIMITED will cut voting power in the company to 0 percent from 25.2 percent

21 Sep 2017

BRIEF- JCR Pharmaceuticals announces business and capital alliance with Medipal Holdings

* Says it signed a business and capital alliance with Medipal Holdings Corp

21 Sep 2017

Earnings vs. Estimates